First DataBank's FIRSTLight Goes Live

First DataBankFirst DataBank's new online medicines reference tool, FIRSTLight, is now live and First DataBank is offering a free extended trial until the end of January 2011. FIRSTLight provides instant access to reliable medicines information, empowering clinicians and supporting safer, faster clinical decision making.

This is the first time First DataBank's trusted medicines information has been available stand alone and accessible at any point in the clinical workflow.

"We introduce FIRSTLight in direct response to requests from individual clinicians and Trusts for instant access to First DataBank's complete electronic medicines information," says Polly Shepperdson, Product Manager at First DataBank.

Several clinical system vendors have expressed early interest in partnering opportunities. Darren Nichols, Managing Director of First DataBank, comments: "Our current business partners are keen to add the immediate value and benefit of FIRSTLight to support their customers' medicines managements needs."

Specific features of FIRSTLight include:

  • How, when and when not to use a medication including ingredients, indications, doses, routes and administration advice
  • When to avoid using a medication, information about allergies and safety of use with other concurrent conditions, drugs and food
  • Tests, measures and observations required while using a medication including what should be done about any resulting changes, along with information about managing expected side effects and what to do in cases of over-dosage
  • Reproduction, pregnancy and breastfeeding advice including whether taking the medication can affect fertility, relevant recommendations for use of contraception and any risks associated with pregancy or breastfeeding while taking the medication.

FIRSTLight iPhone and iPad applications will also be available in early 2011.

To begin using FIRSTLight today, sign up for your free trial at www.firstdatabank.co.uk/firstlight

Related news articles:

About First DataBank
First DataBank is the UK's leading provider of drug knowledge bases and active clinical decision support. With over 30 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, First DataBank has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen First DataBank to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

Our Multilex Drug Data File - the UK's most comprehensive and widely used drug knowledge base - is in daily use by thousands of healthcare professionals in the UK.

For further information visit www.firstdatabank.co.uk.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...